Daily Respiratory Research Analysis
Analyzed 161 papers and selected 3 impactful papers.
Summary
A multicenter stepped-wedge randomized trial showed that enhancing oral care significantly reduced non-ventilator hospital-acquired pneumonia. A large two-cohort analysis supported transitioning spirometry severity classification from percent-predicted values to z-scores with better alignment to clinical outcomes. Separately, bi-allelic loss-of-function variants in TMEM63B were identified as a novel cause of syndromic surfactant dysfunction, linking a mechanosensitive channel to human interstitial lung disease.
Research Themes
- Hospital-acquired pneumonia prevention via oral care
- Modernizing spirometry interpretation using z-scores
- Genetic mechanisms in neonatal/childhood interstitial lung disease
Selected Articles
1. Effectiveness of oral care for the prevention of non-ventilator hospital-acquired pneumonia (HAPPEN): a multicentre, stepped-wedge, cluster-randomised trial in Australia.
In this stepped-wedge cluster RCT across three hospitals (8870 analyzed patients), enhanced oral care reduced NV-HAP with a cumulative hazard ratio of 0.40 versus usual care. Protocol adherence improved markedly (oral care completion 15.9% to 61.9%), while other respiratory infections did not significantly change.
Impact: This pragmatic randomized evaluation demonstrates a scalable, low-cost intervention that significantly prevents NV-HAP, a major and under-addressed hospital complication.
Clinical Implications: Hospitals should implement structured, resourced oral care bundles with staff and patient education and audit-feedback to reduce NV-HAP; quality programs can track adherence and NV-HAP incidence.
Key Findings
- Enhanced oral care reduced NV-HAP with a cumulative hazard ratio of 0.40 compared to usual care.
- Oral care protocol completion increased from 15.9% to 61.9% after implementation.
- No significant reduction was seen in other lower/upper respiratory tract or oral cavity infections.
- Stepped-wedge design enabled ward-level rollout with masked outcome assessment.
Methodological Strengths
- Multicentre stepped-wedge cluster randomized design with masked data collectors
- Intention-to-treat analysis with robust outcome definitions (ECDC criteria)
Limitations
- Potential contamination and variability in implementation across wards
- Generalisability limited to three Australian hospitals; longer-term outcomes not assessed
Future Directions: Evaluate cost-effectiveness, sustainability, and broader scalability across diverse hospital settings; integrate with electronic monitoring to sustain adherence and measure downstream outcomes.
BACKGROUND: Non-ventilator hospital-acquired pneumonia (NV-HAP) is among the most prevalent health-care-associated infections, yet remains under-reported, understudied, and infrequently targeted by infection prevention strategies. Oral care is considered a key preventive measure; however, there are few high-quality randomised controlled trials conducted in hospital settings. The aim of this study is to evaluate whether an enhanced oral care intervention reduces the incidence of NV-HAP. METHODS: The Hospital Acq
2. Z-scores for Spirometry Interpretation: Implications for Classifying Impairments in Lung Function.
Across NHANES (n=14,863) and a COPD health system cohort (n=14,238), shifting to z-score thresholds reclassified 10% and 49% of individuals, respectively, to lesser severity; none were reclassified to higher severity. Those reclassified had lower risks of dyspnea, mortality (HR 0.82), COPD exacerbations (OR 0.45), and hospitalizations.
Impact: Provides outcome-validated evidence supporting z-score thresholds for spirometry, likely informing clinical interpretation standards and quality metrics.
Clinical Implications: Clinicians and labs should transition to z-score–based severity thresholds to better align classification with patient-relevant outcomes; reporting systems and EHRs should support LLN/z-score outputs.
Key Findings
- 10% (NHANES) and 49% (COPD cohort) were reclassified to lesser severity using z-score thresholds.
- No individuals were reclassified to higher severity under z-score criteria.
- Reclassified individuals had lower risks of dyspnea, mortality (HR 0.82), COPD exacerbations (OR 0.45), and hospitalizations.
- Findings support adopting z-scores over percent-predicted for severity classification.
Methodological Strengths
- Two large independent cohorts with consistent findings
- Multivariable analyses linking reclassification to clinically relevant outcomes
Limitations
- Observational design limits causal inference
- Follow-up durations and potential cohort-specific biases are not detailed in the abstract
Future Directions: Prospective validation of z-score thresholds embedded in care pathways; assess impact on treatment decisions, resource use, and patient-reported outcomes.
RATIONALE: Recent guidelines for spirometry interpretation recommend the use of z-scores rather than percent-predicted values to classify the severity of lung function impairment. The potential impact of this change remains unknown. OBJECTIVE: To evaluate the proportion of individuals whose severity classification would change with a transition to z-scores, and to assess how changes in classification are associated with respiratory symptoms and outcomes. METHODS: We evaluated two cohorts of individuals with spirome
3. Bi-allelic loss-of-function variants in TMEM63B cause syndromic surfactant dysfunction disorder.
Across four families (five individuals), bi-allelic loss-of-function TMEM63B variants (splice donor, nonsense, frameshift) were associated with early-onset interstitial lung disease consistent with surfactant dysfunction. Lung histology showed type II pneumocyte hyperplasia with lamellar body abnormalities; functional assays supported loss-of-function.
Impact: Identifies TMEM63B as a new human gene for syndromic surfactant dysfunction, connecting mechanosensitive signaling to alveolar homeostasis with diagnostic and mechanistic implications.
Clinical Implications: Consider TMEM63B sequencing in children with unexplained interstitial lung disease/surfactant dysfunction features; informs genetic counseling and potential stratification for emerging therapies.
Key Findings
- Five individuals from four families had bi-allelic TMEM63B loss-of-function variants (splice donor, nonsense, frameshift).
- Phenotype: early-onset respiratory distress, chronic hypoxemia, diffuse parenchymal changes; some required lung transplantation.
- Lung histology showed type II pneumocyte hyperplasia, lamellar body electron-dense cores, and interstitial fibrosis.
- Functional assays supported a loss-of-function mechanism; phenotype parallels Tmem63b-knockout mice.
Methodological Strengths
- Multimodal evidence: genetics, histopathology, and functional validation
- Cross-species concordance with knockout mouse phenotype
Limitations
- Small cohort inherent to rare disease gene discovery
- Therapeutic implications remain exploratory; no interventional data
Future Directions: Broaden genomic screening to define prevalence and spectrum; model TMEM63B function in human alveolar systems to explore targeted modulation of surfactant secretion.
Transmembrane protein 63B gene (TMEM63B) encodes a mechanosensitive ion channel expressed in alveolar type II epithelial cells, where it mediates stretch-induced surfactant secretion. While heterozygous gain-of-function variants in TMEM63B have been associated with developmental and epileptic encephalopathy, no human disorder has previously been linked to bi-allelic loss-of-function variants. Here, we report five individuals from four unrelated families with childhood interstitial lung disease and bi-allelic pre